

# ForPatients

by Roche

Neoplasms Tumor Cancer

## A Roll Over Study of Alectinib in Patients With Anaplastic Lymphoma Kinase (ALK)-Positive or Rearranged During Transfection (RET)-Positive Cancer

**Trial Status**  
Recruiting

**Trial Runs In**  
10 Countries

**Trial Identifier**  
NCT03194893 2017-000207-24  
BO39694

---

The source of the below information is the publicly available website [ClinicalTrials.gov](https://clinicaltrials.gov). It has been summarised and edited into simpler language.

### *Trial Summary:*

The purpose of this study is to provide continued treatment with alectinib or crizotinib as applicable to participants with ALK- or RET positive cancer who were previously enrolled in any Roche-sponsored alectinib study and who are deriving continued clinical benefit from alectinib or crizotinib in the parent trial at the time of parent trial closure.

**Hoffmann-La Roche**  
Sponsor

**Phase 3**  
Phase

---

**NCT03194893 2017-000207-24 BO39694**  
Trial Identifiers

---

### *Eligibility Criteria:*

**Gender**  
All

**Age**  
All

**Healthy Volunteers**  
No

---